S&P 500   4,052.18 (+0.61%)
DOW   32,828.21 (+0.34%)
QQQ   314.97 (+0.72%)
AAPL   161.42 (+0.40%)
MSFT   282.97 (+0.88%)
META   204.90 (-0.22%)
GOOGL   100.03 (-1.34%)
AMZN   101.51 (+1.26%)
TSLA   195.64 (+0.91%)
NVDA   273.03 (+1.18%)
NIO   10.34 (+5.19%)
BABA   103.76 (+3.84%)
AMD   99.38 (+3.42%)
T   19.09 (+0.47%)
F   12.34 (+2.41%)
MU   63.50 (-0.06%)
CGC   1.82 (+0.50%)
GE   94.06 (+0.00%)
DIS   98.21 (+1.38%)
AMC   5.08 (+1.60%)
PFE   40.34 (+0.22%)
PYPL   74.75 (+0.77%)
NFLX   341.71 (+2.92%)
S&P 500   4,052.18 (+0.61%)
DOW   32,828.21 (+0.34%)
QQQ   314.97 (+0.72%)
AAPL   161.42 (+0.40%)
MSFT   282.97 (+0.88%)
META   204.90 (-0.22%)
GOOGL   100.03 (-1.34%)
AMZN   101.51 (+1.26%)
TSLA   195.64 (+0.91%)
NVDA   273.03 (+1.18%)
NIO   10.34 (+5.19%)
BABA   103.76 (+3.84%)
AMD   99.38 (+3.42%)
T   19.09 (+0.47%)
F   12.34 (+2.41%)
MU   63.50 (-0.06%)
CGC   1.82 (+0.50%)
GE   94.06 (+0.00%)
DIS   98.21 (+1.38%)
AMC   5.08 (+1.60%)
PFE   40.34 (+0.22%)
PYPL   74.75 (+0.77%)
NFLX   341.71 (+2.92%)
S&P 500   4,052.18 (+0.61%)
DOW   32,828.21 (+0.34%)
QQQ   314.97 (+0.72%)
AAPL   161.42 (+0.40%)
MSFT   282.97 (+0.88%)
META   204.90 (-0.22%)
GOOGL   100.03 (-1.34%)
AMZN   101.51 (+1.26%)
TSLA   195.64 (+0.91%)
NVDA   273.03 (+1.18%)
NIO   10.34 (+5.19%)
BABA   103.76 (+3.84%)
AMD   99.38 (+3.42%)
T   19.09 (+0.47%)
F   12.34 (+2.41%)
MU   63.50 (-0.06%)
CGC   1.82 (+0.50%)
GE   94.06 (+0.00%)
DIS   98.21 (+1.38%)
AMC   5.08 (+1.60%)
PFE   40.34 (+0.22%)
PYPL   74.75 (+0.77%)
NFLX   341.71 (+2.92%)
S&P 500   4,052.18 (+0.61%)
DOW   32,828.21 (+0.34%)
QQQ   314.97 (+0.72%)
AAPL   161.42 (+0.40%)
MSFT   282.97 (+0.88%)
META   204.90 (-0.22%)
GOOGL   100.03 (-1.34%)
AMZN   101.51 (+1.26%)
TSLA   195.64 (+0.91%)
NVDA   273.03 (+1.18%)
NIO   10.34 (+5.19%)
BABA   103.76 (+3.84%)
AMD   99.38 (+3.42%)
T   19.09 (+0.47%)
F   12.34 (+2.41%)
MU   63.50 (-0.06%)
CGC   1.82 (+0.50%)
GE   94.06 (+0.00%)
DIS   98.21 (+1.38%)
AMC   5.08 (+1.60%)
PFE   40.34 (+0.22%)
PYPL   74.75 (+0.77%)
NFLX   341.71 (+2.92%)
NASDAQ:GH

Guardant Health - GH Competitors

$23.91
+0.32 (+1.36%)
(As of 03/30/2023 09:45 AM ET)
Add
Compare
Today's Range
$23.80
$24.23
50-Day Range
$22.98
$33.76
52-Week Range
$22.76
$77.72
Volume
71,293 shs
Average Volume
1.99 million shs
Market Capitalization
$2.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.64

GH vs. VCYT, RDNT, VRDN, FLGT, NTRA, TMDX, GDRX, AMED, PACB, and GLPG

Should you be buying Guardant Health stock or one of its competitors? The main competitors of Guardant Health include Veracyte (VCYT), RadNet (RDNT), Viridian Therapeutics (VRDN), Fulgent Genetics (FLGT), Natera (NTRA), TransMedics Group (TMDX), GoodRx (GDRX), Amedisys (AMED), Pacific Biosciences of California (PACB), and Galapagos (GLPG). These companies are all part of the "medical" sector.

Guardant Health vs.

Guardant Health (NASDAQ:GH) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation.

In the previous week, Guardant Health and Guardant Health both had 2 articles in the media. Guardant Health's average media sentiment score of 1.43 beat Veracyte's score of 0.46 indicating that Guardant Health is being referred to more favorably in the media.

Company Overall Sentiment
Guardant Health Positive
Veracyte Neutral

90.4% of Guardant Health shares are owned by institutional investors. 5.9% of Guardant Health shares are owned by company insiders. Comparatively, 2.9% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Guardant Health has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500.

Veracyte has a net margin of -12.33% compared to Guardant Health's net margin of -145.61%. Veracyte's return on equity of -3.42% beat Guardant Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Guardant Health -145.61% -242.65% -35.89%
Veracyte -12.33% -3.42% -3.18%

Veracyte has lower revenue, but higher earnings than Guardant Health. Veracyte is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guardant Health$449.54 million5.39-$654.59 million-$6.40-3.69
Veracyte$296.54 million5.22-$36.56 million-$0.50-42.94

Guardant Health currently has a consensus price target of $57.64, indicating a potential upside of 144.35%. Veracyte has a consensus price target of $30.20, indicating a potential upside of 40.66%. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Guardant Health is more favorable than Veracyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Guardant Health
0 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.85
Veracyte
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Veracyte received 175 more outperform votes than Guardant Health when rated by MarketBeat users. Likewise, 73.26% of users gave Veracyte an outperform vote while only 68.61% of users gave Guardant Health an outperform vote.

CompanyUnderperformOutperform
Guardant HealthOutperform Votes
247
68.61%
Underperform Votes
113
31.39%
VeracyteOutperform Votes
422
73.26%
Underperform Votes
154
26.74%

Summary

Guardant Health beats Veracyte on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GH vs. The Competition

MetricGuardant HealthMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$2.42B$1.73B$4.38B$5.92B
Dividend YieldN/A2.68%2.31%4.51%
P/E Ratio-3.6915.47156.0415.78
Price / Sales5.3947.893,514.4062.16
Price / CashN/A11.2519.9022.50
Price / Book39.983.994.575.11
Net Income-$654.59M-$111.93M$115.26M$191.53M
7 Day Performance-6.17%1.66%1.23%1.54%
1 Month Performance-23.63%-8.54%-6.50%-5.38%
1 Year Performance-65.05%-28.71%-15.63%-18.27%

Guardant Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VCYT
Veracyte
1.8666 of 5 stars
$21.47
+4.3%
$30.20
+40.7%
-30.5%$1.55B$296.54M-42.94761
RDNT
RadNet
2.1962 of 5 stars
$24.13
+0.7%
$30.00
+24.3%
+3.8%$1.40B$1.43B141.949,067
VRDN
Viridian Therapeutics
1.9817 of 5 stars
$25.61
+2.3%
$45.10
+76.1%
+32.1%$1.10B$1.77M-6.3550Analyst Report
Positive News
FLGT
Fulgent Genetics
2.6422 of 5 stars
$29.80
-0.3%
$41.67
+39.8%
-54.2%$879.70M$618.97M6.541,012Short Interest ↑
NTRA
Natera
2.2426 of 5 stars
$56.90
+5.1%
$79.27
+39.3%
+34.1%$6.45B$820.22M-10.223,018Insider Selling
TMDX
TransMedics Group
1.7835 of 5 stars
$73.62
-1.4%
$71.57
-2.8%
+186.1%$2.40B$93.46M-58.90148Positive News
GDRX
GoodRx
2.32 of 5 stars
$6.02
+2.0%
$8.00
+32.9%
-68.6%$2.39B$766.55M-85.99756
AMED
Amedisys
3.0514 of 5 stars
$73.43
+0.5%
$119.53
+62.8%
-58.8%$2.39B$2.22B20.1720,000Short Interest ↓
PACB
Pacific Biosciences of California
1.6161 of 5 stars
$9.58
+4.9%
$11.50
+20.0%
-7.2%$2.37B$128.30M-6.84728News Coverage
GLPG
Galapagos
1.6231 of 5 stars
$37.63
+3.1%
$49.17
+30.7%
-40.6%$2.48B$532.48M-10.971,309Short Interest ↑
This page (NASDAQ:GH) was last updated on 3/30/2023 by MarketBeat.com Staff